BofA lowered the firm’s price target on 89bio (ETNB) to $29 from $30 and keeps a Buy rating on the shares. 89bio’s Q2 report was “highlighted by execution” with key readouts of FGF21 pegozafermin in MASH and SHTG still on track, says the analyst, who cites updated operating expense forecasts for the price target change.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB: